Literature DB >> 22391543

Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae.

Mahableshwar Albur1, Alan Noel, Karen Bowker, Alasdair MacGowan.   

Abstract

The interaction between colistin and tigecycline against eight well-characterized NDM-1-producing Enterobacteriaceae strains was studied. Time-kill methodology was employed using a 4-by-4 exposure matrix with pharmacokinetically achievable free drug peak, trough, and average 24-h serum concentrations. Colistin sulfate and methanesulfonate alone showed good early bactericidal activity, often with subsequent regrowth. Tigecycline alone had poor activity. Addition of tigecycline to colistin does not produce increased bacterial killing; instead, it may cause antagonism at lower concentrations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391543      PMCID: PMC3370758          DOI: 10.1128/AAC.05682-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  J Li; J Turnidge; R Milne; R L Nation; K Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models.

Authors:  Alasdair MacGowan; Karen Bowker
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

3.  In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics.

Authors:  Caroline Rynn; Mandy Wootton; Karen E. Bowker; H. Alan Holt; David S. Reeves
Journal:  Clin Microbiol Infect       Date:  1999-01       Impact factor: 8.067

Review 4.  Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.

Authors:  Yun Cai; Rui Wang; Beibei Liang; Nan Bai; Youning Liu
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

5.  First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain.

Authors:  Mar Solé; Cristina Pitart; Ignasi Roca; Anna Fàbrega; Pilar Salvador; Laura Muñoz; Inés Oliveira; Joaquim Gascón; Francesc Marco; Jordi Vila
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

6.  Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.

Authors:  Rajesh V Dudhani; John D Turnidge; Kingsley Coulthard; Robert W Milne; Craig R Rayner; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

Review 7.  Efficacy and safety of tigecycline: a systematic review and meta-analysis.

Authors:  Dafna Yahav; Adi Lador; Mical Paul; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2011-06-18       Impact factor: 5.790

8.  Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.

Authors:  Laurent Poirel; Emilie Lagrutta; Peter Taylor; Jeanette Pham; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

9.  Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.

Authors:  Nikolaos Markou; Sophia L Markantonis; Efthimios Dimitrakis; Dimitris Panidis; Eleni Boutzouka; Stylianos Karatzas; Petros Rafailidis; Haralampos Apostolakos; George Baltopoulos
Journal:  Clin Ther       Date:  2008-01       Impact factor: 3.393

10.  Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.

Authors:  Jian Li; Kingsley Coulthard; Robert Milne; Roger L Nation; Steven Conway; Daniel Peckham; Christine Etherington; John Turnidge
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790

View more
  21 in total

1.  In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae.

Authors:  Jonathan W Betts; Lynette M Phee; Michael Hornsey; Neil Woodford; David W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Tiffany R Keepers; Marcela Gomez; Chris Celeri; Wright W Nichols; Kevin M Krause
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  Combination Therapy against Polymicrobial Infection, Including by NDM-1-Producing Enterobacteriaceae Resistant to Colistin.

Authors:  Itaru Nakamura; Natsuki Sakamoto; Yukiko Ida; Ryutaro Imai; Kotaro Aoki; Rina Ando; Tetsuo Yamaguchi; Hajime Matsumura; Tetsuya Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

4.  Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.

Authors:  Soon-Ee Cheah; Jian Li; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

5.  Breakthrough bacteremia due to extended-spectrum-β-lactamase-producing Klebsiella pneumoniae during combination therapy with colistin and tigecycline.

Authors:  Sun Young Cho; Cheol-In Kang; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song; Jun Ho Jang
Journal:  Antimicrob Agents Chemother       Date:  2012-09       Impact factor: 5.191

Review 6.  Clinical management of infections caused by multidrug-resistant Enterobacteriaceae.

Authors:  Mercedes Delgado-Valverde; Jesús Sojo-Dorado; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Ther Adv Infect Dis       Date:  2013-04

Review 7.  Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: a case report and literature review.

Authors:  Vindana Chibabhai; Trusha Nana; Norma Bosman; Teena Thomas; Warren Lowman
Journal:  Infection       Date:  2017-09-15       Impact factor: 3.553

Review 8.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 9.  NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings.

Authors:  Wenjing Wu; Yu Feng; Guangmin Tang; Fu Qiao; Alan McNally; Zhiyong Zong
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

10.  Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.

Authors:  George Michail; Maria Labrou; Vassiliki Pitiriga; Styliani Manousaka; Nikolaos Sakellaridis; Athanasios Tsakris; Spyros Pournaras
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.